Overview
Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers.
Background
Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers.
Indication
For the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, for the treatment of magnesium intoxication due to overdosage of magnesium sulfate, and used to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid.
Associated Conditions
- Acute Renal Failure (ARF)
- Dehydration
- Dehydration Hypertonic
- Dry Mouth
- Electrolyte depletion
- End-stage Chronic Kidney Failure
- Fluid Loss
- Hyperkalemia
- Hypocalcemia
- Hypocalcemic tetany
- Hypovolaemia
- Isotonic Dehydration
- Renal Failure, Chronic Renal Failure
- Shock, Hypovolemic
- Beta blocker overdose
- Calcium channel blocker overdose
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/04/22 | Phase 3 | Recruiting | |||
2023/08/03 | Early Phase 1 | Completed | |||
2022/12/23 | Phase 4 | Recruiting | |||
2022/07/01 | Phase 4 | UNKNOWN | Post Graduate Institute of Medical Education and Research, Chandigarh | ||
2021/09/16 | Phase 3 | UNKNOWN | |||
2021/08/30 | Phase 3 | Completed | |||
2020/01/18 | Phase 4 | Terminated | |||
2019/11/06 | Phase 2 | Completed | Lars Wiuff Andersen | ||
2019/03/08 | Phase 1 | Completed | |||
2018/12/12 | Phase 4 | Recruiting | Meshalkin Research Institute of Pathology of Circulation |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Baxter Healthcare Company | 0338-0210 | INTRAVENOUS | 33 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-0210 | INTRAVENOUS | 33 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-0117 | INTRAVENOUS | 20 mg in 100 mL | 10/9/2019 | |
| Medical Purchasing Solutions, LLC | 71872-7193 | INTRAVENOUS | 100 mg in 1 mL | 5/10/2023 | |
| ICU Medical Inc. | 0990-7111 | INTRAVENOUS | 0.2 g in 1000 mL | 6/24/2021 | |
| Fresenius Medical Care North America | 49230-212 | INTRAPERITONEAL | 18.4 mg in 100 mL | 10/19/2023 | |
| Baxter Healthcare Corporation | 0338-0137 | IRRIGATION | 200 mg in 1000 mL | 9/29/2015 | |
| Baxter Healthcare Company | 0338-1147 | INTRAVENOUS | 33 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Corporation | 0338-1147 | INTRAVENOUS | 33 mg in 100 mL | 9/21/2020 | |
| Baxter Healthcare Company | 0338-1142 | INTRAVENOUS | 33 mg in 100 mL | 9/21/2020 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| COMPOUND SODIUM LACTATE INTRAVENOUS INFUSION BP | SIN06429P | INJECTION | 0.027 g/100 ml | 7/8/1991 | |
| LACTATED RINGER'S INJECTION USP | SIN05592P | INJECTION | 20 mg/100 ml | 3/27/1991 | |
| BAXTER-LACTATED RINGER’S INJECTION USP | SIN16604P | INFUSION, SOLUTION | 20mg per 100mL | 9/14/2022 | |
| HAEMODIALYSIS CONCENTRATE NKFS-01 (ACID) FOR BICARBONATE DIALYSIS | SIN09474P | SOLUTION | 7.77 g/l | 8/21/1997 | |
| TISSEEL FIBRIN SEALANT VH S/D (FROZEN) | SIN14707P | SOLUTION | 36-44 umol/ml | 12/22/2014 | |
| BERIPLAST P COMBI-SET 3ML POWDERS AND SOLVENTS FOR SEALANT | SIN16776P | OTHER | 17.7mg | 5/10/2023 | |
| LACTORIDE 500 INFUSION | SIN09647P | INJECTION | 0.027% w/v | 2/18/1998 | |
| ARTISS SOLUTIONS FOR SEALANT, DEEP FROZEN | SIN14719P | SOLUTION | 36 – 44 μmol/ml | 1/6/2015 | |
| BERIPLAST P COMBI-SET 1ML POWDERS AND SOLVENTS FOR SEALANT | SIN16775P | OTHER | 5.9mg | 5/10/2023 | |
| DIANEAL LOW CALCIUM (2.5 mEq/l) PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE | SIN06627P | SOLUTION, STERILE | 18.3 mg/100 ml | 10/14/1991 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Calcium Chloride Injection | 国药准字H20093715 | 化学药品 | 注射剂 | 8/16/2019 | |
| Calcium Chloride Injection | 国药准字H53020818 | 化学药品 | 注射剂 | 8/12/2021 | |
| Calcium Chloride Injection | 国药准字H20258034 | 化学药品 | 注射剂 | 3/21/2025 | |
| Calcium Chloride Injection | 国药准字H20258035 | 化学药品 | 注射剂 | 3/21/2025 | |
| Calcium Chloride Injection | 国药准字H50020146 | 化学药品 | 注射剂 | 8/28/2020 | |
| Calcium Chloride Injection | 国药准字H41021820 | 化学药品 | 注射剂 | 8/14/2020 | |
| Calcium Chloride Injection | 国药准字H53020815 | 化学药品 | 注射剂 | 8/12/2020 | |
| Calcium Chloride Injection | 国药准字H31021659 | 化学药品 | 注射剂 | 4/23/2020 | |
| Calcium Chloride Injection | 国药准字H37022037 | 化学药品 | 注射剂 | 4/17/2020 | |
| Calcium Chloride Injection | 国药准字H53020056 | 化学药品 | 注射剂 | 6/16/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| EXTRANEAL SOLN 7.5% | N/A | N/A | N/A | 8/18/2000 | |
| PRISMASOL B0 SOLUTION FOR HAEMOFILTRATION AND HAEMODIALYSIS | N/A | N/A | N/A | 10/15/2013 | |
| RINGER'S INJ | N/A | otsuka pharmaceutical (h.k.) limited | N/A | N/A | 5/15/2008 |
| LACTATED RINGER'S INJ | N/A | luen cheong hong ltd | N/A | N/A | 5/17/1979 |
| OLIMEL N9E EMULSION FOR INFUSION | N/A | N/A | N/A | 10/24/2013 | |
| NUTRIFLEX OMEGA SPECIAL EMULSION FOR INFUSION | N/A | b. braun medical (hk) ltd | N/A | N/A | 1/11/2012 |
| BALANCE 4.25% GLU. 1.25MMOL/L CAL. P.D. SOLUTION (JAPAN) | N/A | N/A | N/A | 7/12/2005 | |
| WIDA RL RINGER LACTATE INTRAVENOUS INFUSION | N/A | otsuka pharmaceutical (h.k.) limited | N/A | N/A | 10/30/2009 |
| SMOFKABIVEN EMULSION FOR INFUSION | N/A | N/A | N/A | 5/26/2011 | |
| NAMIDA EYE-RUBY EYE DROPS | N/A | eng an trading company limited | N/A | N/A | 5/7/1996 |